Pere Domingo

List of Publications by Year in descending order

396 papers	12,480 citations	34493 54 h-index	51423 90 g-index
418 all docs	418 docs citations	418 times ranked	11493 citing authors

#	Article	IF	Citations
1	HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature Medicine, 2010, 16, 460-465.	15.2	500
2	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498
3	Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infectious Diseases, The, 2013, 13, 927-935.	4.6	333
4	Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection. New England Journal of Medicine, 2003, 349, 1036-1046.	13.9	303
5	Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. Aids, 2002, 16, 209-218.	1.0	267
6	Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1â€“Infected Adults: 48-Week Results From the ASSERT Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 49-57.	0.9	213
7	A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis againstPneumocystis cariniiPneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection. New England Journal of Medicine, 2001, 344, 159-167.	13.9	211
8	Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. Aids, 1999, 13, 2261-2267.	1.0	207
9	Severe Nucleoside-Associated Lactic Acidosis in Human Immunodeficiency Virusâ€“Infected Patients: Report of 12 Cases and Review of the Literature. Clinical Infectious Diseases, 2002, 34, 838-846.	2.9	177
10	Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitorâ€“Experienced Patients With HIV-Associated Lipodystrophy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 229-236.	0.9	143
11	Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2003, 36, 1047-1052.	2.9	139
12	Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. American Journal of Medicine, 2001, 110, 605-609.	0.6	135
13	Dual treatment with lopinavirâ€“ritonavir plus lamivudine versus triple treatment with lopinavirâ€“ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infectious Diseases, The, 2015, 15, 785-792.	4.6	131
14	HIV-1 Infection Alters Gene Expression in Adipose Tissue, Which Contributes to HIV-1/Haart-Associated Lipodystrophy. Antiviral Therapy, 2006, 11, 729-740.	0.6	127
15	Group B Streptococcal Meningitis in Adults: Report of Twelve Cases and Review. Clinical Infectious Diseases, 1997, 25, 1180-1187.	2.9	123
16	FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. Clinical Nutrition, 2017, 36, 861-868.	2.3	123
17	Relationship between current level of immunodeficiency and nonâ€acquired immunodeficiency syndromeâ€defining malignancies. Cancer, 2010, 116, 5306-5315.	2.0	120
18	Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study. Clinical Infectious Diseases, 2004, 38, 565-571.	2.9	118

#	Article	IF	Citations
19	The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). EBioMedicine, 2020, 58, 102887.	2.7	114
20	Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPARÎ³:RXR heterodimers: comparison with other polyunsaturated fatty acids. Journal of Leukocyte Biology, 2008, 84, 1172-1182.	1.5	113
21	A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. Diabetologia, 2013, 56, 2524-2537.	2.9	109
22	Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study. Antiviral Therapy, 2012, 17, 355-364.	0.6	108
23	Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. Aids, 2012, 26, 2315-2326.	1.0	104
24	HIV and antiretroviral therapy-related fat alterations. Nature Reviews Disease Primers, 2020, 6, 48.	18.1	104
25	Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. Diagnostic Microbiology and Infectious Disease, 2006, 56, 153-160.	0.8	98
26	Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten Trial. Antiviral Therapy, 2011, 16, 339-348.	0.6	89
27	Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-FST45 Trial. Clinical Infectious Diseases, 2017, 65, 2112-2118.	2.9	88
28	Primary Meningococcal Conjunctivitis: report of 21 Patients and Review. Clinical Infectious Diseases, 1990, 12, 838-847.	2.9	87
29	Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infectious Diseases, The, 2014, 14, 590-599.	4.6	87
30	Drug-induced lipotoxicity: Lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 392-399.	1.2	86
31	Infectious Pulmonary Nodules in Immunocompromised Patients: Usefulness of Computed Tomography in Predicting Their Etiology. Journal of Computer Assisted Tomography, 2003, 27, 461-468.	0.5	85
32	Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 29-36.	0.9	81
33	Influence of HAART on the Clinical Course of HIV-1-Infected Patients With Progressive Multifocal Leukoencephalopathy: Results of an Observational Multicenter Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 26-31.	0.9	80
34	Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends in Pharmacological Sciences, 2005, 26, 88-93.	4.0	77
35	Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. Clinical Infectious Diseases, 2016, 63, 1668-1676.	2.9	76
36	Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. American Journal of Medicine, 2002, 112, 19-25.	0.6	75

#	Article	IF	Citations
37	Risk of Metabolic Abnormalities in Patients Infected with HIV Receiving Antiretroviral Therapy that Contains Lopinavirâ€Ritonavir. Clinical Infectious Diseases, 2004, 38, 1017-1023.	2.9	75
38	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. Aids, 2005, 19, 569-575.	1.0	75
39	Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. Aids, 2007, 21, 169-178.	1.0	74
40	Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. Aids, 2006, 20, 1407-1414.	1.0	72
41	Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. Journal of Antimicrobial Chemotherapy, 2007, 59, 690-697.	1.3	71
42	Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV,the, 2021, 8, e701-e710.	2.1	69
43	Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. Aids, 2017, 31, 2503-2514.	1.0	65
44	Neuropsychological deficits in patients with cognitive complaints after COVIDâ€19. Brain and Behavior, 2022, 12, e2508.	1.0	64
45	Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitorâ€“Experienced Patients With HIV-Associated Lipodystrophy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 229-236.	0.9	63
46	In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule Cells. Antimicrobial Agents and Chemotherapy, 2006, 50, 3824-3832.	1.4	63
47	Adipose tissue biology and HIV-infection. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 487-499.	2.2	62
48	Body composition changes after switching from protease inhibitors to raltegravir. Aids, 2012, 26, 475-481.	1.0	62
49	Prospective Study of New-Onset Seizures in Patients With Human Immunodeficiency Virus Infection. Archives of Neurology, 1999, 56, 609.	4.9	61
50	Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. Aids, 2001, 15, 1701-1706.	1.0	61
51	A Lopinavir/Ritonavir-Based Once-Daily Regimen Results in Better Compliance and Is Non-inferior to a Twice-Daily Regimen Through 96 Weeks. AIDS Research and Human Retroviruses, 2007, 23, 1505-1514.	0.5	60
52	HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy. Antiviral Therapy, 2006, 11, 729-40.	0.6	60
53	Semiinvasive Pulmonary Aspergillosis in Chronic Obstructive Pulmonary Disease. American Journal of Roentgenology, 2000, 174, 51-56.	1.0	59
54	Switching to Nevirapine Decreases Insulin Levels but Does Not Improve Subcutaneous Adipocyte Apoptosis in Patients with Highly Active Antiretroviral Therapyâ€“Associated Lipodystrophy. Journal of Infectious Diseases, 2001, 184, 1197-1201.	1.9	59

#	Article	IF	Citations
55	The spectrum of acute bacterial meningitis in elderly patients. BMC Infectious Diseases, 2013, 13, 108.	1.3	59
56	96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study. Antiviral Therapy, 2013, 18, 905-913.	0.6	58
57	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. Clinical Infectious Diseases, 2013, 57, 112-121.	2.9	56
58	9-cis-Retinoic Acid (9cRA), a Retinoid X Receptor (RXR) Ligand, Exerts Immunosuppressive Effects on Dendritic Cells by RXR-Dependent Activation: Inhibition of Peroxisome Proliferator-Activated Receptor Î³ Blocks Some of the 9cRA Activities, and Precludes Them to Mature Phenotype Development. Journal of Immunology, 2007, 178, 6130-6139.	0.4	54
59	Morbidity Associated with Longâ€Term Use of Totally Implantable Ports in Patients with AIDS. Clinical Infectious Diseases, 1999, 29, 346-351.	2.9	52
60	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases, 2016, 62, 1571-1577.	2.9	52
61	Air Trapping in Primary SjÃ¶gren Syndrome: Correlation of Expiratory CT with Pulmonary Function Tests. Journal of Computer Assisted Tomography, 1999, 23, 169-173.	0.5	51
62	Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009. AIDS Research and Therapy, 2011, 8, 22.	0.7	50
63	Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms. Journal of Neurology, 2022, 269, 3990-3999.	1.8	50
64	Erythema nodosum and hepatitis C. Lancet, The, 1990, 336, 1377.	6.3	49
65	Spontaneous gram-negative bacillary meningitis in adult patients: characteristics and outcome. BMC Infectious Diseases, 2013, 13, 451.	1.3	49
66	Acute Q Fever in Adult Patients: Report on 63 Sporadic Cases in an Urban Area. Clinical Infectious Diseases, 1999, 29, 874-879.	2.9	48
67	Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients. AIDS Research and Human Retroviruses, 2006, 22, 321-329.	0.5	48
68	Differential Effects of Efavirenz and Lopinavir/Ritonavir on Human Adipocyte Differentiation, Gene Expression and Release of Adipokines and Pro-Inflammatory Cytokines.. Current HIV Research, 2010, 8, 545-553.	0.2	48
69	Bilateral Bell Palsy and Acute HIV Type 1 Infection: Report of 2 Cases and Review. Clinical Infectious Diseases, 2007, 44, e57-e61.	2.9	47
70	Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagnostic Microbiology and Infectious Disease, 2008, 62, 34-43.	0.8	47
71	Differential gene expression indicates that â€˜buffalo humpâ€™ is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy. Aids, 2008, 22, 575-584.	1.0	47
72	Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. Aids, 2010, 24, 2629-2637.	1.0	47

#	Article	IF	Citations
73	The future of antiretroviral therapy: challenges and needs. Journal of Antimicrobial Chemotherapy, 2010, 65, 827-835.	1.3	46
74	Liver-related death among HIV/hepatitis C virus-co-infected individuals. Aids, 2015, 29, 1205-1215.	1.0	46
75	Air-leak Syndromes in Hematopoietic Stem Cell Transplant Recipients With Chronic GVHD. Journal of Thoracic Imaging, 2007, 22, 335-340.	0.8	45
76	Switching to Tenofovir/Emtricitabine from Abacavir/ Lamivudine in HIV-Infected Adults with Raised Cholesterol: Effect on Lipid Profiles. Antiviral Therapy, 2012, 17, 1011-1020.	0.6	45
77	Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines. Antiviral Research, 2016, 132, 59-65.	1.9	45
78	Discontinuation of Primary and SecondaryToxoplasma gondiiProphylaxis Is Safe in HIVâ€Infected Patients after Immunological Restoration with Highly Active Antiretroviral Therapy: Results of an Open, Randomized, Multicenter Clinical Trial. Clinical Infectious Diseases, 2006, 43, 79-89.	2.9	44
79	Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Reviews, 2012, 14, 112-23.	0.5	44
80	Cutaneous angiomas in POEMS syndrome. Journal of the American Academy of Dermatology, 1985, 12, 961-964.	0.6	43
81	Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. Aids, 2011, 25, 1683-1690.	1.0	43
82	Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Research, 2011, 91, 112-119.	1.9	43
83	Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). Journal of Antimicrobial Chemotherapy, 2014, 69, 3368-3371.	1.3	43
84	Fat Distribution and Metabolic Abnormalities in HIV-Infected Patients on First Combination Antiretroviral Therapy Including Stavudine or Zidovudine: Role of Physical Activity as a Protective Factor. Antiviral Therapy, 2003, 8, 223-231.	0.6	43
85	Ultrastructural features of highly active antiretroviral therapy-associated partial lipodystrophy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 441, 599-604.	1.4	42
86	Alternation of Antiretroviral Drug Regimens for HIV Infection. Annals of Internal Medicine, 2003, 139, 81.	2.0	42
87	Improvement of dyslipidemia in patients switching from stavudine to tenofovir. Aids, 2004, 18, 1475-1478.	1.0	42
88	Spanish HIV-1-Infected Long-Term Nonprogressors of More Than 15 Years Have an Increased Frequency of the CX3CR1 249I Variant Allele. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 527-531.	0.9	42
89	Simultaneous Population Pharmacokinetic ModelÂfor Lopinavir and Ritonavir inÂHIV-Infected Adults. Clinical Pharmacokinetics, 2008, 47, 681-692.	1.6	42
90	Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy. Lancet, The, 1997, 349, 1554-1555.	6.3	41

#	Article	IF	Citations
91	Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. Aids, 2006, 20, 2075-2080.	1.0	41
92	Improvement of Mitochondrial Toxicity in Patients Receiving a Nucleoside Reverseâ€Transcriptase Inhibitorâ€“Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clinical Infectious Diseases, 2009, 49, 892-900.	2.9	41
93	Infectionâ€related and â€unrelated malignancies, <scp>HIV</scp> and the aging population. HIV Medicine, 2016, 17, 590-600.	1.0	37
94	Hepatitis C virus and human immunodeficiency virus coinfection in Spain. Journal of Infection, 2003, 47, 117-124.	1.7	36
95	Bacterial Meningitis in HIV-1-Infected Patients in the Era of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 582-587.	0.9	36
96	Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Reviews, 2014, 16, 199-212.	0.5	36
97	Didanosine, Lamivudine, and Efavirenz versus Zidovudine, Lamivudine, and Efavirenz for the Initial Treatment of HIV Type 1 Infection: Final Analysis (48 Weeks) of a Prospective, Randomized, Noninferiority Clinical Trial, GESIDA 3903. Clinical Infectious Diseases, 2008, 47, 1083-1092.	2.9	34
98	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. Open Forum Infectious Diseases, 2016, 3, ofw059.	0.4	34
99	Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines. Immunobiology, 2017, 222, 989-997.	0.8	34
100	Immediate Versus Deferred Switching From a Boosted Protease Inhibitorâ€“based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age â‰¥50 Years: Final 96-Week Results of the NEAT022 Study. Clinical Infectious Diseases, 2019, 68, 597-606.	2.9	34
101	Gynecomastia among HIV-Infected Patients Is Associated with Hypogonadism: A Case-Control Study. Clinical Infectious Diseases, 2004, 39, 1514-1519.	2.9	33
102	The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2008, 62, 234-245.	1.3	33
103	Differentially Altered Molecular Signature of Visceral Adipose Tissue in HIV-1â€“Associated Lipodystrophy. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 142-148.	0.9	33
104	Not all COVID-19 pandemic waves are alike. Clinical Microbiology and Infection, 2021, 27, 1040.e7-1040.e10.	2.8	33
105	Prieumococcal bacteraemia in immunocompetent adults. Lancet, The, 1991, 337, 57.	6.3	32
106	Failure of a Short-Term Prednisone Regimen to Prevent Nevirapine-Associated Rash: A Double-Blind Placebo-Controlled Trial: The GESIDA 09/99 Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 14-18.	0.9	32
107	Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. HIV Medicine, 2019, 20, 237-247.	1.0	32
108	Acute Appendicitis Complicating Infectious Mononucleosis: Case Report and Review. Clinical Infectious Diseases, 1990, 12, 297-302.	2.9	31

#	Article	IF	Citations
109	Pulmonary Thrombosis or Embolism in a Large Cohort of Hospitalized Patients With Covid-19. Frontiers in Medicine, 2020, 7, 557.	1.2	31
110	Pharmacogenetics of adverse effects due to antiretroviral drugs. AIDS Reviews, 2010, 12, 15-30.	0.5	31
111	Effects of Rilpivirine on Human Adipocyte Differentiation, Gene Expression, and Release of Adipokines and Cytokines. Antimicrobial Agents and Chemotherapy, 2012, 56, 3369-3375.	1.4	30
112	Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy Controls. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 207-212.	0.9	30
113	Effects of Metformin Or Gemfibrozil on the Lipodystrophy of HIV-Infected Patients Receiving Protease Inhibitors. Antiviral Therapy, 2003, 8, 403-410.	0.6	30
114	Clinical Utility of Maraviroc. Clinical Drug Investigation, 2011, 31, 527-542.	1.1	29
115	Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. AIDS Reviews, 2010, 12, 3-14.	0.5	29
116	HIV-1 Infection in Subjects Older than 70: A Multicenter Cross-Sectional Assessment in Catalonia, Spain. Current HIV Research, 2009, 7, 597-600.	0.2	28
117	The Changing Face of HIV/AIDS in Treated Patients. Current HIV Research, 2009, 7, 365-377.	0.2	28
118	Relationship between HIV/Highly Active Antiretroviral Therapy (HAART)â€“Associated Lipodystrophy Syndrome and Stavudineâ€Triphosphate Intracellular Levels in Patients with Stavudineâ€Based Antiretroviral Regimens. Clinical Infectious Diseases, 2010, 50, 1033-1040.	2.9	28
119	Hiv-1 Tat Protein Impairs Adipogenesis and Induces the Expression and Secretion of Proinflammatory Cytokines in Human Sgbs Adipocytes. Antiviral Therapy, 2012, 17, 529-540.	0.6	28
120	Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue. Aging Cell, 2018, 17, e12822.	3.0	28
121	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology, 0, 13, .	2.2	28
122	Effect of Genetic Variants of CCR2 and CCL2 on the Natural History of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 132-138.	0.9	27
123	First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. Journal of Antimicrobial Chemotherapy, 2008, 61, 1348-1358.	1.3	27
124	The changing pattern of bacterial meningitis in adult patients at a large tertiary university hospital in Barcelona, Spain (1982â€“2010). Journal of Infection, 2013, 66, 147-154.	1.7	27
125	Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals. PLoS ONE, 2014, 9, e114142.	1.1	27
126	Reverse Transcriptase Inhibitors Alter Uncoupling Protein-1 and Mitochondrial Biogenesis in Brown Adipocytes. Antiviral Therapy, 2005, 10, 515-526.	0.6	27

#	Article	IF	Citations
127	Once-Daily Regimen of Saquinavir, Ritonavir, Didanosine, and Lamivudine in HIV-Infected Patients With Standard Tuberculosis Therapy (TBQD Study). Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 317-323.	0.9	26
128	Renal Safety of Tenofovir Disoproxil Fumarate in HIV-1 Treatment-experienced Patients with Adverse Events Related to Prior NRTI Use. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 385-387.	0.9	26
129	Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. Journal of Antimicrobial Chemotherapy, 2010, 65, 2195-2203.	1.3	26
130	Leptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophy. Cytokine, 2012, 58, 253-260.	1.4	26
131	Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial. Clinical Infectious Diseases, 2015, 60, 811-820.	2.9	26
132	A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients. Aids, 2018, 32, 565-573.	1.0	26
133	Epidemiological trends of HIV infection in Spain. Aids, 2002, 16, 2496-2499.	1.0	26
134	Dyslipidemia and Cardiovascular Disease Risk Factor Management in HIV-1-Infected Subjects Treated with HAART in the Spanish VACH Cohort. Open AIDS Journal, 2008, 2, 26-38.	0.1	26
135	Evans's Syndrome Triggered by Recombinant Hepatitis B Vaccine. Clinical Infectious Diseases, 1992, 15, 1051-1051.	2.9	25
136	Erratum. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 396.	0.9	25
137	HIV-1-Infected Long-Term Non-Progressors have Milder Mitochondrial Impairment and Lower Mitochondrially-Driven Apoptosis in Peripheral Blood Mononuclear Cells than Typical Progressors. Current HIV Research, 2007, 5, 467-473.	0.2	25
138	Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. Aids, 2007, 21, 367-369.	1.0	25
139	Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. Journal of Antimicrobial Chemotherapy, 2015, 70, 2104-2107.	1.3	25
140	Uncoupling protein 1 gene expression implicates brown adipocytes in highly active antiretroviral therapy-associated lipomatosis. Aids, 2004, 18, 959-960.	1.0	24
141	Effect of TNF-Î± genetic variants and CCR5Î”32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards. BMC Medical Genetics, 2010, 11, 63.	2.1	24
142	Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus Atazanavir Each with Zidovudine/Lamivudine. Antiviral Therapy, 2012, 17, 337-346.	0.6	24
143	Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2012, 67, 2479-2486.	1.3	24
144	Adipogenic/Lipid, Inflammatory, and Mitochondrial Parameters in Subcutaneous Adipose Tissue of Untreated HIV-1â€“Infected Long-Term Nonprogressors. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 131-137.	0.9	24

#	Article	IF	Citations
145	Methicillin-Resistant Staphylococcus aureus Meningitis in Adults. Medicine (United States), 2012, 91, 10-17.	0.4	24
146	Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation. Cytokine, 2013, 61, 808-815.	1.4	24
147	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. Aids, 2018, 32, 1995-2004.	1.0	24
148	Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort. PLoS ONE, 2015, 10, e0145701.	1.1	24
149	Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Journal of Medical Virology, 2005, 77, 23-28.	2.5	23
150	Polymorphism of RANTES Chemokine Gene Promoter Is Not Associated With Long-Term Nonprogressive HIV-1 Infection of More Than 16 Years. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 17-22.	0.9	23
151	The IL-6 system in HIV-1-infection and in HAART-related fat redistribution syndromes. Aids, 2008, 22, 893-896.	1.0	23
152	Effects of Switching from Stavudine to Raltegravir on Subcutaneous Adipose Tissue in HIV-Infected Patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A Clinical and Molecular Study. PLoS ONE, 2014, 9, e89088.	1.1	23
153	Virological Efficacy in Cerebrospinal Fluid and Neurocognitive Status in Patients with Long-Term Monotherapy Based on Lopinavir/Ritonavir: An Exploratory Study. PLoS ONE, 2013, 8, e70201.	1.1	22
154	Human Papillomavirus Infection in HIV-1 Infected Women in Catalonia (Spain): Implications for Prevention of Cervical Cancer. PLoS ONE, 2012, 7, e47755.	1.1	22
155	Altered expression of master regulatory genes of adipogenesis in lipomas from patients bearing tRNALys point mutations in mitochondrial DNA. Molecular Genetics and Metabolism, 2006, 89, 283-285.	0.5	21
156	Association of ITPA Gene Polymorphisms and the Risk of Ribavirin-Induced Anemia in HIV/Hepatitis C Virus (HCV)-Coinfected Patients Receiving HCV Combination Therapy. Antimicrobial Agents and Chemotherapy, 2012, 56, 2987-2993.	1.4	21
157	Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients. HIV Clinical Trials, 2012, 13, 61-69.	2.0	21
158	Fat Tissue Measurements by Dual-Energy X-Ray Absorptiometry: Cross-Calibration of 3 Different Fan-Beam Instruments. Journal of Clinical Densitometry, 2013, 16, 212-222.	0.5	21
159	Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 152-160.	0.9	21
160	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2015, 70, 1139-1145.	1.3	21
161	Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant. Open Forum Infectious Diseases, 2018, 5, ofx258.	0.4	21
162	Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 373-379.	0.3	21

#	Article	IF	Citations
163	Altered Expression of Nucleoside Transporter Genes (SLC28 and SLC29) in Adipose Tissue from HIV-1â€“Infected Patients. Antiviral Therapy, 2007, 12, 853-864.	0.6	21
164	Bacterial Meningitis with â€œNormalâ€•Cerebrospinal Fluid in Adults: A Report on Five Cases. Scandinavian Journal of Infectious Diseases, 1990, 22, 115-116.	1.5	20
165	Lipodystrophy and Insulin Resistance in Combination Antiretroviral Treated HIV-1â€“Infected Patients: Implication of Resistin. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 16-23.	0.9	20
166	Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. Journal of Antimicrobial Chemotherapy, 2011, 66, 358-362.	1.3	20
167	Drug safety profile of integrase strand transfer inhibitors. Expert Opinion on Drug Safety, 2014, 13, 431-445.	1.0	20
168	Hemorrhagic Stroke as a Complication of Bacterial Meningitis in Adults: Report of Three Cases and Review. Clinical Infectious Diseases, 1995, 21, 1488-1491.	2.9	19
169	Meningococcal Meningitis During Penicillin Therapy for Meningococcemia. Clinical Infectious Diseases, 1997, 25, 1479-1479.	2.9	19
170	Lopinavir/Ritonavir Pharmacokinetics in HIV and Hepatitis C Virus Co-Infected Patients without Liver Function Impairment. Clinical Pharmacokinetics, 2007, 46, 85-92.	1.6	19
171	Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 390-396.	0.9	19
172	Comparative Effectiveness of Initial Antiretroviral Therapy Regimens. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 253-260.	0.9	19
173	Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. Journal of Antimicrobial Chemotherapy, 2014, 69, 1390-1396.	1.3	19
174	Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS). Journal of Antimicrobial Chemotherapy, 2014, 69, 1653-1659.	1.3	19
175	Very low level viraemia and risk of virological failure in treated <scp>HIV</scp>â€1â€infected patients. HIV Medicine, 2017, 18, 196-203.	1.0	19
176	Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV. International Journal of Obesity, 2020, 44, 1970-1973.	1.6	19
177	Efavirenz-Induced Leukocytoclastic Vasculitis. Archives of Internal Medicine, 2002, 162, 355-a-356.	4.3	19
178	Epidemiological trends of HIV infection in Spain: preventative plans have to be oriented to new target populations (Spanish VACH Cohort). Aids, 2002, 16, 2496-9.	1.0	19
179	Liver Triglyceride Content in HIV-1-Infected Patients on Combination Antiretroviral Therapy Studied with ¹H-MR Spectroscopy. Antiviral Therapy, 2007, 12, 195-204.	0.6	19
180	Lack of Association of SDF-1 3â€²A Variant Allele With Long-Term Nonprogressive HIV-1 Infection Is Extended Beyond 16 Years. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 276-279.	0.9	18

#	Article	IF	Citations
181	Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults. Aids, 2008, 22, 377-384.	1.0	18
182	Restoration of T Cell Responses to Toxoplasma gondii after Successful Combined Antiretroviral Therapy in Patients with AIDS with Previous Toxoplasmic Encephalitis. Clinical Infectious Diseases, 2011, 52, 662-670.	2.9	18
183	Reduced Levels of Serum FGF19 and Impaired Expression of Receptors for Endocrine FGFs in Adipose Tissue From HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 527-534.	0.9	18
184	Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. Journal of Antimicrobial Chemotherapy, 2014, 70, 1130-8.	1.3	18
185	Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain. HIV Clinical Trials, 2015, 16, 57-65.	2.0	18
186	Air trapping in COVID-19 patients following hospital discharge: retrospective evaluation with paired inspiratory/expiratory thin-section CT. European Radiology, 2022, 32, 4427-4436.	2.3	18
187	Management of Complications Associated with Totally Implantable Ports in Patients with AIDS. AIDS Patient Care and STDs, 2001, 15, 7-13.	1.1	17
188	Thymidine Kinase 2 Deficiency-Induced Mitochondrial DNA Depletion Causes Abnormal Development of Adipose Tissues and Adipokine Levels in Mice. PLoS ONE, 2011, 6, e29691.	1.1	17
189	Short-Term and Long-Term Clinical and Immunological Consequences of Stopping Antiretroviral Therapy in HIV-Infected Patients with Preserved Immune Function. Antiviral Therapy, 2013, 18, 125-130.	0.6	17
190	Lipotoxicity on the Basis of Metabolic Syndrome and Lipodystrophy in HIV-1-Infected Patients Under Antiretroviral Treatment. Current Pharmaceutical Design, 2010, 16, 3372-3378.	0.9	17
191	Simplification Therapy with Once-Daily Didanosine, Tenofovir and Efavirenz in HIV-1-Infected Adults with Viral Suppression Receiving a More Complex Antiretroviral Regimen: Final Results of the EFADITE Trial. Antiviral Therapy, 2005, 10, 825-832.	0.6	17
192	Lateral Decubitus CT. American Journal of Roentgenology, 2000, 174, 528-530.	1.0	16
193	Failure of Cetirizine to Prevent Nevirapine-Associated Rash. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1276-1281.	0.9	16
194	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV Type 1-Infected Patients Using a Nonnucleoside Reverse Transcriptase Inhibitor-Based or a Boosted Protease Inhibitor-Based Antiretroviral Regimen: Three-Year Results (The Advanz Trial): A Randomized, Controlled Trial. AIDS Research and Human Retroviruses, 2010, 26, 747-757.	0.5	16
195	Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study. BMJ Open, 2021, 11, e051237.	0.8	16
196	Could mitochondrial DNA quantitation be a surrogate marker for drug mitochondrial toxicity?. AIDS Reviews, 2004, 6, 169-80.	0.5	16
197	Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1â€“Infected, Treatment-NaÃ¯ve ARTEMIS Patients at Week 96. HIV Clinical Trials, 2011, 12, 313-322.	2.0	15
198	Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08). European Journal of Public Health, 2012, 22, 802-808.	0.1	15

#	Article	IF	Citations
199	High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients. Metabolism: Clinical and Experimental, 2017, 71, 163-170.	1.5	15
200	Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy. Atherosclerosis, 2018, 273, 28-36.	0.4	15
201	High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients. EBioMedicine, 2020, 62, 103077.	2.7	15
202	Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. Clinical Immunology, 2021, 223, 108631.	1.4	15
203	Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. Trials, 2021, 22, 808.	0.7	15
204	Alpha variant SARS-CoV-2 infection: How it all starts. EBioMedicine, 2021, 74, 103703.	2.7	15
205	Impaired expression of mitochondrial and adipogenic genes in adipose tissue from a patient with acquired partial lipodystrophy (Barraquer-Simons syndrome): a case report. Journal of Medical Case Reports, 2008, 2, 284.	0.4	14
206	Efficacy and Safety of Switching from Enfuvirtide to Raltegravir in Patients with Virological Suppression. HIV Clinical Trials, 2009, 10, 432-438.	2.0	14
207	HIV-1 Infection and the PPAR<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>-Dependent Control of Adipose Tissue Physiology. PPAR Research, 2009, 2009, 1-8.	1.1	14
208	Polyradiculoneuropathy Associated to Human Herpesvirus 2 in an HIV-1-Infected Patient (Elsberg) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	14
209	Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen. Journal of Antimicrobial Chemotherapy, 2012, 67, 1453-1458.	1.3	14
210	Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA. Aids, 2012, 26, 2165-2174.	1.0	14
211	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2014, 32, 447-458.	0.3	14
212	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1â€“Infected Patients Starting Efavirenz, Lopinavirâ€“Ritonavir, or Atazanavirâ€“Ritonavir Plus Tenofovir/Emtricitabine. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 206-215.	0.9	14
213	Glycoprotein Profile Assessed by 1H-NMR as a Global Inflammation Marker in Patients with HIV Infection. A Prospective Study. Journal of Clinical Medicine, 2020, 9, 1344.	1.0	14
214	The Molecular Signature of HIV-1-Associated Lipomatosis Reveals Differential Involvement of Brown and Beige/Brite Adipocyte Cell Lineages. PLoS ONE, 2015, 10, e0136571.	1.1	14
215	Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19. Diagnostics, 2021, 11, 1998.	1.3	14
216	Epidemiological trends of HIV/HCV coinfection in Spain, 2015â€“2019. HIV Medicine, 2022, 23, 705-716.	1.0	14

#	Article	IF	Citations
217	Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor. Antiviral Therapy, 2003, 8, 223-31.	0.6	14
218	Lipodystrophy in HIV-1-infected patients. Lancet, The, 1999, 354, 868.	6.3	13
219	Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort. BMC Women's Health, 2011, 11, 36.	0.8	13
220	Response to Combined Antiretroviral Therapy According to Gender and Origin in a Cohort of NaÃ¯ve HIV-Infected Patients: GESIDA-5808 Study. HIV Clinical Trials, 2012, 13, 131-141.	2.0	13
221	Effects of docosahexanoic acid supplementation on inflammatory and subcutaneous adipose tissue gene expression in HIV-infected patients on combination antiretroviral therapy (cART). A sub-study of a randomized, double-blind, placebo-controlled study. Cytokine, 2018, 105, 73-79.	1.4	13
222	Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. Aids, 2018, 32, 2807-2819.	1.0	13
223	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. Journal of Antimicrobial Chemotherapy, 2021, 76, 2380-2393.	1.3	13
224	Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet HIV,the, 2021, 8, e463-e473.	2.1	13
225	PPARγ Pro12Ala Polymorphism in HIV-1-Infected Patients with HAARTRelated Lipodystrophy. Current HIV Research, 2009, 7, 533-540.	0.2	13
226	Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. Journal of Antimicrobial Chemotherapy, 2022, 77, 2265-2273.	1.3	13
227	Trimethoprim-Sulfamethoxazole-Induced Renal Tubular Acidosis in a Patient with AIDS. Clinical Infectious Diseases, 1995, 20, 1435-1437.	2.9	12
228	Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. Aids, 2005, 19, 1385-1391.	1.0	12
229	Impact of Switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on Body Fat Redistribution in Virologically Suppressed HIV-Infected Adults. AIDS Research and Human Retroviruses, 2011, 27, 1061-1065.	0.5	12
230	Association of Thymidylate Synthase Gene Polymorphisms with Stavudine Triphosphate Intracellular Levels and Lipodystrophy. Antimicrobial Agents and Chemotherapy, 2011, 55, 1428-1435.	1.4	12
231	A 48-Week Study of Fat Molecular Alterations in HIV Naive Patients Starting Tenofovir/Emtricitabine With Lopinavir/Ritonavir or Efavirenz. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 457-465.	0.9	12
232	Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1825-1832.	1.3	12
233	Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 517-523.	0.3	12
234	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 88-99.	0.3	12

#	Article	IF	Citations
235	Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254. Clinical Infectious Diseases, 2022, 75, 786-794.	2.9	12
236	Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients. Antiviral Therapy, 2007, 12, 853-63.	0.6	12
237	Cerebrospinal Fluid Adenosine Deaminase Levels in a Patient with Cryptococcal Meningitis. Clinical Infectious Diseases, 1992, 15, 1061-1062.	2.9	11
238	Tuberculous Pulmonary Gangrene: Report of a Case and Review. Clinical Infectious Diseases, 1994, 18, 243-245.	2.9	11
239	Role of Baseline Human Immunodeficiency Virus Genotype as a Predictor of Viral Response to Tenofovir in Heavily Pretreated Patients. Journal of Clinical Microbiology, 2003, 41, 4421-4423.	1.8	11
240	No Relationship BetweenTNF-Î±Genetic Variants and Combination Antiretroviral Therapy-Related Lipodystrophy Syndrome in HIV Type 1-Infected Patients: A Case-Control Study and a Meta-Analysis. AIDS Research and Human Retroviruses, 2011, 27, 143-152.	0.5	11
241	Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 516.e1-516.e18.	0.3	11
242	Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/Î²-Klotho System. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
243	Uridine Metabolism in HIV-1-Infected Patients: Effect of Infection, of Antiretroviral Therapy and of HIV-1/ART-Associated Lipodystrophy Syndrome. PLoS ONE, 2010, 5, e13896.	1.1	11
244	Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission. Scientific Reports, 2022, 12, 640.	1.6	11
245	Brain biopsy for intracranial mass lesions in AIDS. Lancet, The, 1993, 341, 242-243.	6.3	10
246	Disseminated Cytomegalovirus Infection in an Immunocompetent Adult Successfully Treated with Ganciclovir. Scandinavian Journal of Infectious Diseases, 1995, 27, 523-525.	1.5	10
247	Epstein-Barr Virus Infection Associated with Interstitial Nephritis and Chronic Fatigue. Scandinavian Journal of Infectious Diseases, 1996, 28, 185-187.	1.5	10
248	Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/Î¼l or less. Aids, 2004, 18, 1727-1729.	1.0	10
249	Strategies in the treatment of HIV-1-associated adipose redistribution syndromes. Expert Opinion on Pharmacotherapy, 2007, 8, 1871-1884.	0.9	10
250	Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. Journal of Infection, 2012, 64, 204-211.	1.7	10
251	Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 81-101.	1.5	10
252	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 544-556.	0.3	10

#	Article	IF	Citations
253	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 361-371.	0.3	10
254	Characteristics and outcome of spontaneous bacterial meningitis in patients with cancer compared to patients without cancer. Medicine (United States), 2017, 96, e6899.	0.4	10
255	Does choice of antiretroviral drugs matter for inflammation?. Expert Review of Clinical Pharmacology, 2019, 12, 389-396.	1.3	10
256	Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIVâ€“1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). Clinical Infectious Diseases, 2021, 73, e1991-e1999.	2.9	10
257	Association of Thymidylate Synthase Polymorphisms with Acute Pancreatitis and/or Peripheral Neuropathy in HIV-Infected Patients on Stavudine-Based Therapy. PLoS ONE, 2013, 8, e57347.	1.1	10
258	Liver Involvement in Acute Q Fever. Chest, 1988, 94, 895-896.	0.4	9
259	Acute Bacterial Meningitis in the Elderly. Archives of Internal Medicine, 1990, 150, 1546.	4.3	9
260	HIV Type-1 Transgene Expression in Mice Alters Adipose Tissue and Adipokine Levels: Towards a Rodent Model of HIV Type-1 Lipodystrophy. Antiviral Therapy, 2010, 15, 1021-1028.	0.6	9
261	Prevalence of Transmitted Antiretroviral Resistance and Distribution of HIV-1 Subtypes Among Patients with Recent Infection in Catalonia (Spain) between 2003 and 2005. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 482-489.	0.3	9
262	Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS. Expert Opinion on Pharmacotherapy, 2013, 14, 1055-1064.	0.9	9
263	Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease. Aids, 2015, 29, 1493-1504.	1.0	9
264	Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw504.	1.3	9
265	Bacterial meningitis: the end of the beginning?. Lancet Infectious Diseases, The, 2016, 16, 271-272.	4.6	9
266	Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia. Aids, 2018, 32, 1309-1316.	1.0	9
267	Establishing a hepatitis C continuum of care among <scp>HIV</scp>/hepatitis C virusâ€coinfected individuals in Euro<scp>SIDA</scp>. HIV Medicine, 2019, 20, 264-273.	1.0	9
268	Tolerability of Current Antiretroviral Single-Tablet Regimens. AIDS Reviews, 2019, 20, 141-149.	0.5	9
269	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 195-202.	0.3	9
270	Linezolid for therapy of Staphylococcus aureus meningitis: a cohort study of 26 patients. Infectious Diseases, 2020, 52, 808-815.	1.4	9

#	Article	IF	Citations
271	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). Expert Opinion on Pharmacotherapy, 2021, 22, 1127-1141.	0.9	9
272	FGF21 serum levels are related to insulin resistance, metabolic changes and obesity in Mexican people living with HIV (PLWH). PLoS ONE, 2021, 16, e0252144.	1.1	9
273	Moraxella catarrhalis BacterÃ¦mia in an Immunocompetent Adult. Scandinavian Journal of Infectious Diseases, 1995, 27, 95-95.	1.5	8
274	Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2007, 61, 206-209.	1.3	8
275	Zidovudine/Lamivudine/Abacavir Plus Tenofovir in HIV-Infected Naive Patients: A 96-Week Prospective One-Arm Pilot Study. AIDS Research and Human Retroviruses, 2008, 24, 931-934.	0.5	8
276	Etravirine: Clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antiviral Therapy, 2010, 15, 803-816.	0.6	8
277	Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1365-1382.	1.5	8
278	Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers. Journal of Antimicrobial Chemotherapy, 2012, 67, 2013-2019.	1.3	8
279	Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection. Expert Opinion on Drug Safety, 2012, 11, 473-485.	1.0	8
280	Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. BMC Public Health, 2021, 21, 1596.	1.2	8
281	Previous Vitamin D Supplementation and Morbidity and Mortality Outcomes in People Hospitalised for COVID19: A Cross-Sectional Study. Frontiers in Public Health, 2021, 9, 758347.	1.3	8
282	Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. Aids, 2002, 16, 1299-1301.	1.0	8
283	Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists. European Journal of Rheumatology, 2020, 7, S107-S109.	1.3	8
284	Consensus document on the management of renal disease in HIV-infected patients. Nefrologia, 2014, 34 Suppl 2, 1-81.	0.2	8
285	Successful liver transplantation using a polycystic donor liver. Journal of Hepatology, 1997, 26, 1428.	1.8	7
286	Absence of Mutations in Exon 8 of the LMNA Gene in Combination Antiretroviral Therapy-Associated Partial Lipodystrophy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 457-458.	0.9	7
287	Mechanisms of antiretroviral-induced mitochondrial dysfunction in adipocytes and adipose tissue: in-vitro, animal and human adipose tissue studies. Current Opinion in HIV and AIDS, 2007, 2, 261-267.	1.5	7
288	Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. Antiviral Therapy, 2011, 17, 577-583.	0.6	7

#	Article	IF	Citations
289	Combination antiretroviral therapy. Expert Opinion on Pharmacotherapy, 2011, 12, 995-998.	0.9	7
290	Short Communication: High Effectiveness of Etravirine in Routine Clinical Practice in Treatment-Experienced HIV Type 1-Infected Patients. AIDS Research and Human Retroviruses, 2011, 27, 713-717.	0.5	7
291	Effectiveness and safety of an abacavir/lamivudineâ€Š+â€Šrilpivirine regimen for the treatment of HIV-1 infection in naive patients. Journal of Antimicrobial Chemotherapy, 2016, 71, 3510-3514.	1.3	7
292	Executive summary of the consensus document on osteoporosis in HIV-infected individuals. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 312-314.	0.3	7
293	Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 151-159.	0.3	7
294	Standing on the shoulders of giants: two centuries of struggle against meningococcal disease. Lancet Infectious Diseases, The, 2019, 19, e284-e294.	4.6	7
295	Characteristics and outcome of spontaneous bacterial meningitis in patients with diabetes mellitus. BMC Infectious Diseases, 2020, 20, 292.	1.3	7
296	Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19. PLoS ONE, 2022, 17, e0262777.	1.1	7
297	Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes. Antiviral Therapy, 2005, 10, 515-26.	0.6	7
298	Â2-Microglobulin and Immunoglobulins are More Useful Markers of Disease Progression in HIV than Neopterin and Adenosine Deaminase. Annals of Clinical Biochemistry, 1999, 36, 601-608.	0.8	6
299	Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort. Journal of Antimicrobial Chemotherapy, 2008, 63, 189-196.	1.3	6
300	Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40âˆ¶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients. PLoS ONE, 2013, 8, e67035.	1.1	6
301	An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes. Expert Opinion on Pharmacotherapy, 2014, 15, 1749-1760.	0.9	6
302	Efficacy and tolerability after 24weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIVâ€“HCV coinfected subjects. Antiviral Research, 2014, 104, 59-61.	1.9	6
303	Drug therapies for HIV-related metabolic disorders. Expert Opinion on Pharmacotherapy, 2016, 17, 1327-1338.	0.9	6
304	Costâ€“effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 16-20.	0.3	6
305	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 268-276.	0.3	6
306	Drug-drug interactions when treating HIV-related metabolic disorders. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 787-802.	1.5	6

#	Article	IF	Citations
307	Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping. Journal of Antimicrobial Chemotherapy, 2020, 75, 3517-3524.	1.3	6
308	Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy. Antiviral Therapy, 2007, 12, 195-203.	0.6	6
309	Consumptive coagulopathy associated with aortic aneurysm. American Journal of Medicine, 1987, 83, 189-190.	0.6	5
310	Sore throat, antibiotics, and progression to meningococcal disease. Lancet, The, 1995, 345, 460.	6.3	5
311	Disseminated cryptococcosis resembling milliary tuberculosis in an HIV-1-infected patient. Lancet Infectious Diseases, The, 2005, 5, 189.	4.6	5
312	Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2010, 28, 266-272.	0.3	5
313	Expression of human and mouse adenine nucleotide translocase (ANT) isoform genes in adipogenesis. International Journal of Biochemistry and Cell Biology, 2015, 64, 34-44.	1.2	5
314	Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. AIDS Research and Human Retroviruses, 2017, 33, 29-32.	0.5	5
315	Effects of docosahexanoic acid on metabolic and fat parameters in HIV-infected patients on cART: A randomized, double-blind, placebo-controlled study. Clinical Nutrition, 2018, 37, 1340-1347.	2.3	5
316	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. Nefrologia, 2019, 39, 497-505.	0.2	5
317	Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. Journal of Antimicrobial Chemotherapy, 2020, 75, 3334-3343.	1.3	5
318	Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV. PLoS ONE, 2021, 16, e0249515.	1.1	5
319	Riesgo de enfermedad cardiovascular en pacientes con infecciÃ³n VIH en tratamiento antirretroviral. Revista Clinica Espanola, 2020, 220, 149-154.	0.2	5
320	Cellulitis after axillary lymph node dissection. American Journal of Medicine, 1994, 97, 201-202.	0.6	4
321	Effect of Protease Inhibitors on Apolipoprotein B Levels and Plasma Lipid Profile in HIV-1â€“Infected Patients on Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 114-116.	0.9	4
322	Saquinavir/Ritonavir Monotherapy as a New Nucleoside-Sparing Maintenance Strategy in Long-Term Virologically Suppressed HIVInfected Patients. Current HIV Research, 2010, 8, 467-470.	0.2	4
323	Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens. Journal of Antimicrobial Chemotherapy, 2012, 67, 1462-1469.	1.3	4
324	ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study. Journal of the International AIDS Society, 2014, 17, 19814.	1.2	4

#	Article	IF	Citations
325	Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients. BioMed Research International, 2014, 2014, 1-8.	0.9	4
326	Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients. Pharmacogenomics, 2014, 15, 569-572.	0.6	4
327	Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study. HIV Clinical Trials, 2015, 16, 43-48.	2.0	4
328	Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study. Journal of Antimicrobial Chemotherapy, 2018, 73, 2171-2176.	1.3	4
329	IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status. Scientific Reports, 2019, 9, 15722.	1.6	4
330	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. Journal of Antimicrobial Chemotherapy, 2020, 75, 1955-1960.	1.3	4
331	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. Aids, 2021, 35, 2025-2033.	1.0	4
332	HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels. PLoS ONE, 2015, 10, e0144789.	1.1	4
333	HCV reinfection after HCV therapy among HIV/HCVâ€coinfected individuals in Europe. HIV Medicine, 2022, 23, 684-692.	1.0	4
334	The Predictive Value of Petechiae in Adults With Bacterial Meningitis. JAMA - Journal of the American Medical Association, 1986, 256, 2820.	3.8	3
335	Multiple Myeloma With Polyneuropathy and Coagulopathy. Archives of Internal Medicine, 1986, 146, 2089.	4.3	3
336	Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy. Expert Review of Endocrinology and Metabolism, 2011, 6, 21-30.	1.2	3
337	Psychopathology and psychosocial adjustment in patients with HIV-associated lipodystrophy. Brazilian Journal of Infectious Diseases, 2013, 17, 444-449.	0.3	3
338	Safety, Efficacy, and Persistence of Emtricitabine/Tenofovir Versus Other Nucleoside Analogues in Naive Subjects Aged 50 Years or Older in Spain: The TRIP Study. HIV Clinical Trials, 2013, 14, 204-215.	2.0	3
339	Improved adipose tissue function with initiation of protease inhibitor-only ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 3212-3221.	1.3	3
340	Switching antiretroviral regimes for the treatment of HIV: safety implications. Expert Opinion on Drug Safety, 2016, 15, 1349-1360.	1.0	3
341	Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 1346-1351.	1.3	3
342	Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical index. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 149-158.	0.3	3

#	Article	IF	Citations
343	Neisseria meningitidis and purpura fulminans in a woman with chronic liver disease. Lancet Infectious Diseases, The, 2017, 17, 459.	4.6	3
344	Resolved heart tamponade and controlled exophthalmos, facial pain and diabetes insipidus due to Erdheim-Chester disease. BMJ Case Reports, 2018, 2018, bcr-2018-225224.	0.2	3
345	Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 248-257.	0.9	3
346	Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2. Medicine (United States), 2021, 100, e25923.	0.4	3
347	Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). Open Forum Infectious Diseases, 2022, 9, ofab595.	0.4	3
348	Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy. International Journal of Molecular Sciences, 2022, 23, 2202.	1.8	3
349	Vaccination against HBV in France. Lancet, The, 1999, 353, 414.	6.3	2
350	99m Tc-HMPAO SPET: a method to study visual loss in cryptococcal meningitis. Acta Neurologica Scandinavica, 2000, 102, 340-341.	1.0	2
351	Inmunoterapia y vacunas terapÃ©uticas en la infecciÃ³n por VIH. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2005, 23, 84-94.	0.3	2
352	Absence of CXCR4 C-Terminal Polymorphisms in HIV-1-Infected and Uninfected Spaniards. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 382-383.	0.9	2
353	Polymorphisms in the 3â€² untranslated region of the fractalkine (CX3CL1) gene and the risk of HIV-1 infection and disease progression. Aids, 2007, 21, 891-893.	1.0	2
354	Evaluation of the Safety and Effectiveness of Nevirapine Plus Coformulated Tenofovir/Emtricitabine as First-Line Therapy in Routine Clinical Practice. AIDS Research and Human Retroviruses, 2012, 28, 165-170.	0.5	2
355	Hypertrophied Facial Fat in An HIV-1-Infected Patient after Autologous Transplantation from â€˜Buffalo Humpâ€™ Retains a Partial Brown-Fat-Like Molecular Signature. Antiviral Therapy, 2013, 18, 1-5.	0.6	2
356	Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naÃ¯ve patients. Journal of the International AIDS Society, 2014, 17, 19773.	1.2	2
357	Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir. HIV Medicine, 2016, 17, 340-349.	1.0	2
358	Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy. HIV Clinical Trials, 2016, 17, 89-95.	2.0	2
359	HIV/HCV Coinfection in Spain: Prevalence and Patient Characteristics. Journal of Hepatology, 2016, 64, S617.	1.8	2
360	Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERAÂ®, Because of a Previous Intolerance to cART. PRO-STR Study. Current HIV Research, 2019, 16, 425-435.	0.2	2

#	Article	IF	Citations
361	Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study. Current HIV Research, 2012, 10, 673-678.	0.2	2
362	Standardized Comparison of Cardiovascular Risk Factors Prevalence in Spanish Women and Men Living with HIV and in the General Population. Journal of Personalized Medicine, 2021, 11, 1085.	1.1	2
363	Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy. Journal of Clinical Medicine, 2022, 11, 549.	1.0	2
364	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. HIV Medicine, 2022, 23, 585-598.	1.0	2
365	Pulmonary Infections in People Living with HIV. Radiologic Clinics of North America, 2022, 60, 507-520.	0.9	2
366	Acute Q Fever. Archives of Internal Medicine, 1990, 150, 695.	4.3	1
367	Bacterial meningitis and the painful eye. Lancet, The, 1996, 347, 122-123.	6.3	1
368	Invasive pneumococcal disease in HIV-1 infected patients. Lancet, The, 1996, 347, 1414.	6.3	1
369	Immunotherapy and therapeutic vaccines in HIV infection. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2005, 23, 95-104.	0.3	1
370	Editorial [Hot topic: Targets of Metabolic Toxicity of HIV Antiretroviral Drugs: The Multiple Roads to Lipodystrophy and Metabolic Syndrome (Executive Editors: Pere Domingo and Francesc Villarroya)]. Current Pharmaceutical Design, 2010, 16, 3337-3338.	0.9	1
371	Atazanavir dose reduction: one size does not fit all. Lancet HIV,the, 2016, 3, e334-e335.	2.1	1
372	ART regimes and fat: the healing hand wielding the sword. Lancet HIV,the, 2017, 4, e2-e3.	2.1	1
373	Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 481-490.	0.9	1
374	Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2019, 37, 151-159.	0.2	1
375	Long-term efficacy and safety of nevirapine-containing regimens in virologically suppressed patients: a 17-year follow up. HIV Research and Clinical Practice, 2019, 20, 151-155.	1.1	1
376	Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study. Nefrologia, 2019, 39, 497-505.	0.2	1
377	The pharmacological management of cardiovascular disease in people living with HIV (PLWH). Expert Opinion on Pharmacotherapy, 2021, 22, 743-753.	0.9	1
378	Absence of Mutations in Exon 8 of the LMNA Gene in Combination Antiretroviral Therapy-Associated Partial Lipodystrophy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 457-458.	0.9	1

#	Article	IF	Citations
379	Adipose tissue aging partially accounts for fat alterations in HIV lipodystrophy. Adipocyte, 2022, 11, 143-152.	1.3	1
380	Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort. Infectious Diseases and Therapy, 2022, 11, 1177-1192.	1.8	1
381	Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. Journal of Antimicrobial Chemotherapy, 2022, , .	1.3	1
382	Executive summary of the consensus document on the management of renal disease in HIV-infected patients. Nefrologia, 2014, 34, 768-88.	0.2	1
383	Antibiotic prophylaxis and endocarditis. Lancet, The, 1992, 339, 738.	6.3	0
384	Aerosolized pentamidine prophylaxis of Pneumocystis carinii pneumonia in HIV-infected patients. American Journal of Medicine, 1995, 98, 101-102.	0.6	0
385	Antiagregantes plaquetarios y su influencia en la estancia hospitalaria y consumo de recursos sanitarios en pacientes ancianos con fractura de fÃ©mur. Revista De Calidad Asistencial: Ã³rgano De La Sociedad EspaÃ±ola De Calidad Asistencial, 2005, 20, 251-255.	0.6	0
386	Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. Antiviral Therapy, 2012, 17, 597.	0.6	0
387	Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy. HIV Clinical Trials, 2017, 18, 49-53.	2.0	0
388	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 88-99.	0.2	0
389	Costâ€“effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2018, 36, 16-20.	0.2	0
390	Circulating metabolomic profile indicates mitochondrial dysfunction in HIV-dyslipidemia. Atherosclerosis, 2018, 275, e149.	0.4	0
391	A baseline metabolomic signature is associated with immunological CD4+ T-Cell recovery after 36 months of art in HIV-infected patients. Atherosclerosis, 2018, 275, e33.	0.4	0
392	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2018, 36, 268-276.	0.2	0
393	Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-NaÃ¯ve Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). SSRN Electronic Journal, 0, , .	0.4	0
394	Meningococcemia. , 2001, , 473-502.		0
395	Esophageal Ulcers in AIDS. Annals of Internal Medicine, 1996, 124, 928.	2.0	0
396	eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort. HIV Research and Clinical Practice, 2021, 22, 78-85.	1.1	0